OTCMKTS:EDTXF Spectral Diagnostics (EDTXF) Stock Price, News & Analysis $0.79 -0.03 (-3.21%) As of 02:25 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsShort Interest About Spectral Diagnostics Stock (OTCMKTS:EDTXF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spectral Diagnostics alerts:Sign Up Key Stats Today's Range$0.76▼$0.8550-Day Range$0.82▼$1.0252-Week Range$0.76▼$1.15Volume56,241 shsAverage Volume9,573 shsMarket Capitalization$233.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Spectral Diagnostics, now known as Spectral Medical Inc., is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation. Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis. The assay is intended to support physicians in assessing patients and selecting potential treatment strategies. The company has also been involved in the development and commercialization of blood-purification therapies, including polymyxin B hemoperfusion, which is designed to remove endotoxins from the bloodstream. Spectral Medical serves the critical-care and hospital markets, with operations and commercial activities focused primarily in North America and other international markets through regulatory and distribution relationships.AI Generated. May Contain Errors. Read More Receive EDTXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectral Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDTXF Stock News HeadlinesSpectral Medical Announces U.S. FDA Filing of PMA Application for PMXJune 25, 2026 | globenewswire.comSpectral Medical Inc. Announces Results of Annual and Special Meeting of ShareholdersJune 9, 2026 | globenewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 21 at 1:00 AM | Banyan Hill Publishing (Ad)Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris TrialJune 4, 2026 | globenewswire.comSpectral Medical Announces PMA Submission to U.S. FDA for PMXMay 29, 2026 | globenewswire.comSpectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 8, 2026 | globenewswire.comSpectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate UpdateMarch 26, 2026 | globenewswire.comSpectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory MedicineMarch 24, 2026 | globenewswire.comSee More Headlines EDTXF Stock Analysis - Frequently Asked Questions How have EDTXF shares performed this year? Spectral Diagnostics' stock was trading at $1.02 at the beginning of 2026. Since then, EDTXF shares have decreased by 22.2% and is now trading at $0.7937. How were Spectral Diagnostics' earnings last quarter? Spectral Diagnostics Inc. (OTCMKTS:EDTXF) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.00. The firm earned $0.64 million during the quarter, compared to the consensus estimate of $0.54 million. How do I buy shares of Spectral Diagnostics? Shares of EDTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2026Today9/21/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:EDTXF Previous SymbolOTCMKTS:DIAGF CIKN/A Webwww.spectraldx.com Phone(416) 626-3233Fax416-626-7383Employees29Year Founded1991Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.13 million Net Margins-1,393.13% Pretax Margin-1,387.92% Return on EquityN/A Return on Assets-652.72% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.03 Sales & Book Value Annual Sales$1.75 million Price / Sales133.63 Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-4.67Miscellaneous Outstanding Shares294,640,000Free Float290,221,000Market Cap$233.86 million OptionableNot Optionable Beta0.16 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:EDTXF) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectral Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectral Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.